• 48
  • 6
  • 1

Ocugen: WHO Approval For Covaxin Is Potentially A Red Herring For Investors

Seeking Alpha2021-11-04

Summary Ocugen missed the opportunity to grab an Emergency Use Authorization for Covaxin in the US earlier this year, but it could still gain an approval via a pivotal immuno-bridging study. ...

网页链接

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论6

  • MasterDrive
    ·2021-11-05
    this is the reason why it dumped
    回复
    举报
  • Likelike
    ·2021-11-04
    very detailed and well thought analysis,superb thanks...like like...
    回复
    举报
  • MuffinsDaddy
    ·2021-11-04
    Ol
    回复
    举报
    收起
  • Kave
    ·2021-11-04
    [开心] [开心] 
    回复
    举报
  • PCQ
    ·2021-11-04
    interesting
    回复
    举报
    收起
    • D199991D
      Yup
      2021-11-04
      回复
      举报
    • Kave
      [开心] [开心]
      2021-11-04
      回复
      举报
  • iamjingxian
    ·2021-11-04
    Cool
    回复
    举报
    收起
 
 
 
 

热议股票

 
 
 
 
 

7x24